These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 22112807)

  • 1. Improved cortisol exposure-time profile and outcome in patients with adrenal insufficiency: a prospective randomized trial of a novel hydrocortisone dual-release formulation.
    Johannsson G; Nilsson AG; Bergthorsdottir R; Burman P; Dahlqvist P; Ekman B; Engström BE; Olsson T; Ragnarsson O; Ryberg M; Wahlberg J; Biller BM; Monson JP; Stewart PM; Lennernäs H; Skrtic S
    J Clin Endocrinol Metab; 2012 Feb; 97(2):473-81. PubMed ID: 22112807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved Urinary Cortisol Metabolome in Addison Disease: A Prospective Trial of Dual-Release Hydrocortisone.
    Espiard S; McQueen J; Sherlock M; Ragnarsson O; Bergthorsdottir R; Burman P; Dahlqvist P; Ekman B; Engström BE; Skrtic S; Wahlberg J; Stewart PM; Johannsson G
    J Clin Endocrinol Metab; 2021 Mar; 106(3):814-825. PubMed ID: 33236103
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improving glucocorticoid replacement therapy using a novel modified-release hydrocortisone tablet: a pharmacokinetic study.
    Johannsson G; Bergthorsdottir R; Nilsson AG; Lennernas H; Hedner T; Skrtic S
    Eur J Endocrinol; 2009 Jul; 161(1):119-30. PubMed ID: 19383806
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circadian hydrocortisone infusions in patients with adrenal insufficiency and congenital adrenal hyperplasia.
    Merza Z; Rostami-Hodjegan A; Memmott A; Doane A; Ibbotson V; Newell-Price J; Tucker GT; Ross RJ
    Clin Endocrinol (Oxf); 2006 Jul; 65(1):45-50. PubMed ID: 16817818
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Achieving a physiological cortisol profile with once-daily dual-release hydrocortisone: a pharmacokinetic study.
    Johannsson G; Lennernäs H; Marelli C; Rockich K; Skrtic S
    Eur J Endocrinol; 2016 Jul; 175(1):85-93. PubMed ID: 27129362
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Usefulness of Time-Point Serum Cortisol and ACTH Measurements for the Adjustment of Glucocorticoid Replacement in Adrenal Insufficiency.
    Rousseau E; Joubert M; Trzepla G; Parienti JJ; Freret T; Vanthygem MC; Desailloud R; Lefebvre H; Coquerel A; Reznik Y;
    PLoS One; 2015; 10(8):e0135975. PubMed ID: 26317782
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Replacement therapy of oral hydrocortisone in adrenal insufficiency: the influence of gastrointestinal factors.
    Lennernäs H; Skrtic S; Johannsson G
    Expert Opin Drug Metab Toxicol; 2008 Jun; 4(6):749-58. PubMed ID: 18611115
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Weight-related dosing, timing and monitoring hydrocortisone replacement therapy in patients with adrenal insufficiency.
    Mah PM; Jenkins RC; Rostami-Hodjegan A; Newell-Price J; Doane A; Ibbotson V; Tucker GT; Ross RJ
    Clin Endocrinol (Oxf); 2004 Sep; 61(3):367-75. PubMed ID: 15355454
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual-release hydrocortisone improves body composition and the glucometabolic profile in patients with secondary adrenal insufficiency.
    Jørgensen NT; Boesen VB; Borresen SW; Christoffersen T; Jørgensen NR; Plomgaard P; Christoffersen C; Watt T; Feldt-Rasmussen U; Klose M
    Endocrine; 2024 Jun; 84(3):1182-1192. PubMed ID: 38345683
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of oral hydrocortisone - Results and implications from a randomized controlled trial.
    Werumeus Buning J; Touw DJ; Brummelman P; Dullaart RPF; van den Berg G; van der Klauw MM; Kamp J; Wolffenbuttel BHR; van Beek AP
    Metabolism; 2017 Jun; 71():7-16. PubMed ID: 28521880
    [TBL] [Abstract][Full Text] [Related]  

  • 11. What is the best approach to tailoring hydrocortisone dose to meet patient needs in 2012?
    Debono M; Ross RJ
    Clin Endocrinol (Oxf); 2013 May; 78(5):659-64. PubMed ID: 23194144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circadian hormone profiles and insulin sensitivity in patients with Addison's disease: a comparison of continuous subcutaneous hydrocortisone infusion with conventional glucocorticoid replacement therapy.
    Björnsdottir S; Øksnes M; Isaksson M; Methlie P; Nilsen RM; Hustad S; Kämpe O; Hulting AL; Husebye ES; Løvås K; Nyström T; Bensing S
    Clin Endocrinol (Oxf); 2015 Jul; 83(1):28-35. PubMed ID: 25400085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An oral multiparticulate, modified-release, hydrocortisone replacement therapy that provides physiological cortisol exposure.
    Whitaker M; Debono M; Huatan H; Merke D; Arlt W; Ross RJ
    Clin Endocrinol (Oxf); 2014 Apr; 80(4):554-561. PubMed ID: 23980724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of two different doses of hydrocortisone on cognition in patients with secondary adrenal insufficiency--results from a randomized controlled trial.
    Werumeus Buning J; Brummelman P; Koerts J; Dullaart RP; van den Berg G; van der Klauw MM; Tucha O; Wolffenbuttel BH; van Beek AP
    Psychoneuroendocrinology; 2015 May; 55():36-47. PubMed ID: 25705800
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized, double-blind, crossover study comparing two- and four-dose hydrocortisone regimen with regard to quality of life, cortisol and ACTH profiles in patients with primary adrenal insufficiency.
    Ekman B; Bachrach-Lindström M; Lindström T; Wahlberg J; Blomgren J; Arnqvist HJ
    Clin Endocrinol (Oxf); 2012 Jul; 77(1):18-25. PubMed ID: 22288685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of once-daily, modified-release hydrocortisone versus standard glucocorticoid therapy on metabolism and innate immunity in patients with adrenal insufficiency (DREAM): a single-blind, randomised controlled trial.
    Isidori AM; Venneri MA; Graziadio C; Simeoli C; Fiore D; Hasenmajer V; Sbardella E; Gianfrilli D; Pozza C; Pasqualetti P; Morrone S; Santoni A; Naro F; Colao A; Pivonello R; Lenzi A
    Lancet Diabetes Endocrinol; 2018 Mar; 6(3):173-185. PubMed ID: 29229498
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decrease in salivary cortisol levels after glucocorticoid dose reduction in patients with adrenal insufficiency: A prospective proof-of-concept study.
    Ceccato F; Barbot M; Lizzul L; Selmin E; Saller A; Albiger N; Betterle C; Boscaro M; Scaroni C
    Clin Endocrinol (Oxf); 2018 Feb; 88(2):201-208. PubMed ID: 28973827
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective evaluation of long-term safety of dual-release hydrocortisone replacement administered once daily in patients with adrenal insufficiency.
    Nilsson AG; Marelli C; Fitts D; Bergthorsdottir R; Burman P; Dahlqvist P; Ekman B; Engström BE; Olsson T; Ragnarsson O; Ryberg M; Wahlberg J; Lennernäs H; Skrtic S; Johannsson G
    Eur J Endocrinol; 2014 Sep; 171(3):369-77. PubMed ID: 24944332
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Switching From Immediate-Release to Fractionated Dual-Release Hydrocortisone May Improve Metabolic Control and QoL in Selected Primary Adrenal Insufficiency Patients.
    Delle Cese F; Corsello A; Cintoni M; Locantore P; Pontecorvi A; Corsello SM; Paragliola RM
    Front Endocrinol (Lausanne); 2020; 11():610904. PubMed ID: 33597926
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiometabolic and psychological effects of dual-release hydrocortisone: a cross-over study.
    Dineen R; Martin-Grace J; Ahmed KMS; Frizelle I; Gunness A; Garrahy A; Hannon AM; O'Reilly MW; Smith D; McDermott J; Healy ML; Agha A; Pazderska A; Gibney J; Thompson CJ; Behan LA; Sherlock M
    Eur J Endocrinol; 2021 Feb; 184(2):253-265. PubMed ID: 33513125
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.